- La Joie, Renaud;
- Ayakta, Nagehan;
- Seeley, William W;
- Borys, Ewa;
- Boxer, Adam L;
- DeCarli, Charles;
- Doré, Vincent;
- Grinberg, Lea T;
- Huang, Eric;
- Hwang, Ji‐Hye;
- Ikonomovic, Milos D;
- Jack, Clifford;
- Jagust, William J;
- Jin, Lee‐Way;
- Klunk, William E;
- Kofler, Julia;
- Lesman‐Segev, Orit H;
- Lockhart, Samuel N;
- Lowe, Val J;
- Masters, Colin L;
- Mathis, Chester A;
- McLean, Catriona L;
- Miller, Bruce L;
- Mungas, Daniel;
- O'Neil, James P;
- Olichney, John M;
- Parisi, Joseph E;
- Petersen, Ronald C;
- Rosen, Howard J;
- Rowe, Christopher C;
- Spina, Salvatore;
- Vemuri, Prashanthi;
- Villemagne, Victor L;
- Murray, Melissa E;
- Rabinovici, Gil D
Introduction
We sought to establish the relationships between standard postmortem measures of AD neuropathology and antemortem [11C]PIB-positron emission tomography ([11C]PIB-PET) analyzed with the Centiloid (CL) method, a standardized scale for Aβ-PET quantification.Methods
Four centers contributed 179 participants encompassing a broad range of clinical diagnoses, PET data, and autopsy findings.Results
CL values increased with each CERAD neuritic plaque score increment (median -3 CL for no plaques and 92 CL for frequent plaques) and nonlinearly with Thal Aβ phases (increases were detected starting at phase 2) with overlap between scores/phases. PET-pathology associations were comparable across sites and unchanged when restricting the analyses to the 56 patients who died within 2 years of PET. A threshold of 12.2 CL detected CERAD moderate-to-frequent neuritic plaques (area under the curve = 0.910, sensitivity = 89.2%, specificity = 86.4%), whereas 24.4 CL identified intermediate-to-high AD neuropathological changes (area under the curve = 0.894, sensitivity = 84.1%, specificity = 87.9%).Discussion
Our study demonstrated the robustness of a multisite Centiloid [11C]PIB-PET study and established a range of pathology-based CL thresholds.